Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Price:
0.036
USD
-12.2%
Market Closed
Market Cap:
$9.5m
Balance Sheet
Balance Sheet Decomposition
Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics PLC
Balance Sheet Decomposition is not available for
Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics PLC
Balance Sheet
Adaptimmune Therapeutics PLC
Adaptimmune Therapeutics PLC
Currency: USD
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
194
|
159
|
84
|
68
|
50
|
57
|
150
|
108
|
144
|
91
|
|
| Cash Equivalents |
194
|
159
|
84
|
68
|
50
|
57
|
150
|
108
|
144
|
91
|
|
| Short-Term Investments |
55
|
23
|
124
|
137
|
39
|
311
|
220
|
97
|
3
|
60
|
|
| Total Receivables |
1
|
2
|
0
|
18
|
21
|
21
|
34
|
38
|
47
|
16
|
|
| Accounts Receivables |
1
|
2
|
0
|
0
|
0
|
0
|
1
|
7
|
1
|
1
|
|
| Other Receivables |
0
|
0
|
0
|
18
|
21
|
21
|
33
|
31
|
46
|
15
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
|
| Other Current Assets |
13
|
16
|
22
|
8
|
10
|
9
|
12
|
13
|
14
|
13
|
|
| Total Current Assets |
263
|
199
|
230
|
231
|
121
|
398
|
416
|
255
|
208
|
188
|
|
| PP&E Net |
13
|
28
|
41
|
36
|
52
|
47
|
51
|
72
|
72
|
51
|
|
| PP&E Gross |
13
|
28
|
41
|
36
|
52
|
47
|
51
|
72
|
72
|
51
|
|
| Accumulated Depreciation |
2
|
5
|
10
|
16
|
24
|
31
|
36
|
39
|
46
|
52
|
|
| Intangible Assets |
0
|
1
|
1
|
2
|
2
|
2
|
1
|
0
|
0
|
4
|
|
| Other Long-Term Assets |
9
|
7
|
9
|
8
|
7
|
5
|
2
|
2
|
3
|
3
|
|
| Total Assets |
286
N/A
|
235
-18%
|
281
+20%
|
277
-2%
|
182
-34%
|
451
+149%
|
470
+4%
|
329
-30%
|
283
-14%
|
246
-13%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
8
|
11
|
8
|
4
|
6
|
6
|
8
|
5
|
8
|
9
|
|
| Accrued Liabilities |
7
|
16
|
27
|
20
|
26
|
30
|
32
|
32
|
36
|
36
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
13
|
13
|
39
|
0
|
2
|
3
|
23
|
28
|
29
|
20
|
|
| Total Current Liabilities |
28
|
40
|
74
|
24
|
34
|
39
|
63
|
65
|
73
|
65
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
50
|
|
| Other Liabilities |
23
|
28
|
4
|
5
|
24
|
71
|
201
|
183
|
170
|
119
|
|
| Total Liabilities |
51
N/A
|
68
+35%
|
78
+14%
|
30
-62%
|
58
+94%
|
110
+90%
|
264
+140%
|
247
-6%
|
243
-2%
|
234
-4%
|
|
| Equity | |||||||||||
| Common Stock |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
|
| Retained Earnings |
90
|
162
|
232
|
319
|
456
|
586
|
744
|
909
|
1 023
|
1 094
|
|
| Additional Paid In Capital |
332
|
341
|
455
|
574
|
586
|
936
|
960
|
991
|
1 065
|
1 106
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Other Equity |
8
|
14
|
22
|
10
|
7
|
10
|
11
|
0
|
4
|
2
|
|
| Total Equity |
235
N/A
|
166
-29%
|
203
+22%
|
247
+22%
|
124
-50%
|
341
+176%
|
206
-40%
|
82
-60%
|
40
-52%
|
12
-70%
|
|
| Total Liabilities & Equity |
286
N/A
|
235
-18%
|
281
+20%
|
277
-2%
|
182
-34%
|
451
+149%
|
470
+4%
|
329
-30%
|
283
-14%
|
246
-13%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
425
|
425
|
562
|
628
|
631
|
929
|
938
|
987
|
1 363
|
1 536
|
|
Switch to:
Switch to:
See Also
Discover More
